Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease

Abstract Introduction Deutetrabenazine is a vesicular monoamine transporter 2 inhibitor used to treat tardive dyskinesia (TD) and chorea associated with Huntington disease (HD). To enhance detection of safety signals across individual trials, integrated safety analyses of deutetrabenazine in TD and...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Samuel Frank, Karen E. Anderson, Hubert H. Fernandez, Robert A. Hauser, Daniel O. Claassen, David Stamler, Stewart A. Factor, Joohi Jimenez-Shahed, Hadas Barkay, Amanda Wilhelm, Jessica K. Alexander, Nayla Chaijale, Steve Barash, Juha-Matti Savola, Mark Forrest Gordon, Maria Chen
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Adis, Springer Healthcare 2024-04-01
Ráidu:	Neurology and Therapy
Fáttát:	Chorea Deutetrabenazine Huntington disease Movement disorders Safety profile Tardive dyskinesia
Liŋkkat:	https://doi.org/10.1007/s40120-024-00600-1
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!